[Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
Primary central nervous system lymphoma (PCNSL) is a non-Hodgkin's lymphoma arising in the central nervous system. Combined irradition and methotrexate-based chemotherapy is the standard of care treatment for PCNSL. The median overall survival achieved with this therapy is 25 to 51 months. Failure after first-line treatment has been reported in most patients with PCNSL. Salvage therapy is known to improve outcome, and although many different treatment modes have been attempted the optimal treatment schedule remains to be determined. This review analyses the efficacy of salvage therapy by focusing on data obtained from reports reporting on salvage therapy. Well-designed, randomized trials will help clarify issues such as the best chemotherapy regimen for second-line treatment.
Yamanaka
Ryuya
R
Research Center of Innovative Cancer Therapy, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka 830-0011, Japan.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D055808:Drug Discovery; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000532:radiotherapy*; D008727:Methotrexate / Q000008:administration & dosage*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy; D000069283:Rituximab; D016879:Salvage Therapy; D000077204:Temozolomide; D019772:Topotecan / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D003606:Dacarbazine; D019772:Topotecan; D000077204:Temozolomide; D008727:Methotrexate